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Interleukin-33 (IL-33) is a well-recognized immunomodulatory cytokine which plays
critical roles in tissue function and immune-mediated diseases. The abundant expression
of IL-33 in brain and spinal cord prompted many scientists to explore its unique role in the
central nervous system (CNS) under physiological and pathological conditions. Indeed
emerging evidence from over a decade’s research suggests that IL-33 acts as one of the
key molecular signaling cues coordinating the network between the immune and CNS
systems, particularly during the development of neurological diseases. Here, we highlight
the recent advances in our knowledge regarding the distribution and cellular localization
of IL-33 and its receptor ST2 in speciﬁc CNS regions, and more importantly the key roles
IL-33/ST2 signaling pathway play in CNS function under normal and diseased conditions.
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INTRODUCTION
The active and extensive communication between the immune and central nervous system (CNS)
is essential in maintaining homeostasis of the CNS and mediating the pathogenesis of neurological
diseases. Over recent decades, rapid development in the area suggests many immune cytokines
play pivotal roles facilitating this complex neuroimmune crosstalk, and interleukin-33 (IL-33) is
one such key cytokine.
IL-33, amember of IL-1 cytokine family, was first identified in 2005 (1) as the ligand for ST2 (also
known as IL-1RL1) (2). Extensive research in the following years has shown that full length IL-33 is
bioactive and can be released by living cells (3), or by necrotic cells following tissue damage acting
as an endogenous danger signal or alarmin [reviewed previously (4, 5)]. In apoptotic cells, IL-33 is
inactivated by released caspases (6). IL-33 binds to ST2 and then recruits IL-1 receptor accessory
protein (IL-1RAcP), which leads to the activation of MyD88 and NF-κB signaling pathway (7).
Soluble ST2 (sST2), a decoy receptor for IL-33, binds to IL-33, and blocks its function. While IL-33
is expressed by many types of cells, in particular stromal and tissue barrier cells and some innate
immune cells, ST2 is expressed by various immune cells including T cells, B cells, macrophages,
dendritic cells, and innate lymphoid cells (7). The IL-33/ST2 signaling pathway has pleitropic
functions in a range of infectious and inflammatory diseases often with dual roles, mediating both
pathological immune responses and tissue repair (4, 8–11).
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Remarkably IL-33 is expressed constitutively within the
brain and spinal cord tissues. Around 33% of isolated brain
cells of naïve mouse are IL-33 positive (12) and its mRNA
expression level is higher than any other tissues and organs
tested (1). These findings together with the recent evidence
of ST2 expression by CNS resident cells (13, 14) indicate a
unique role for the IL-33/ST2 signaling pathway within the CNS.
Indeed accumulating evidence in recent years suggests that IL-
33 mediates the interaction between immune, endothelial and
CNS resident cells and plays a key role in the development and
homeostasis of the CNS. IL-33 is also prominently involved in
the neuroinflammation of many neurological diseases such as
Alzheimer’s disease (AD) and multiple sclerosis (MS) through
action mechanisms beyond immunomodulation (15, 16).
This paper will summarize the current findings of the
expression of IL-33 and ST2 in different regions and cells of the
CNS. This is an area which remains poorly characterized and
sometimes controversial, however it constitutes a key step toward
our understanding of the function of IL-33/ST2 axis in CNS. We
will then discuss the functional implications of the IL-33/ST2
signaling pathway in the CNS compartment under normal and
diseased conditions.
DIVERSE EXPRESSION OF IL-33 AND ITS
RECEPTOR ST2 IN CNS REGIONS AND
CELLS
IL-33 Expression
Despite suggestions from Wicher et al. that IL-33 is only
expressed in CNS during late embryogenesis and becoming
absent in adult brain (17), others show that its expression is
increased during postnatal development (16, 18). IL-33 is also
constitutively highly expressed in adult CNS tissues in both
human andmouse (13, 16, 19, 20). Interestingly the levels of IL-33
expression across brain and spinal cord regions are not uniform
and constant, which potentially reflects specific functions of
the IL-33/ST2 signaling pathway in region-associated neuronal
activities and disorders. IL-33 expression is particularly abundant
in white matter areas such as: corpus callosum (CC) (12, 21)
and the anterior forceps of the CC (fmi) (Figure 1A), anterior
commissure (aco) (Figure 1B), hippocampal fringe (fi) and the
stria terminalus (st) (Figure 1C) (21, 22). IL-33 expression
is also distributed throughout the olfactory cortex as well as
scattered expression in the somatosensory (S1) and motor cortex
(M1/M2; Figure 1D). While the hippocampus is another region
which is often affected during CNS inflammatory diseases,
in particular AD, a disease accompanied by cognition and
memory impairments (23), hippocampal expression of IL-33 is
surprisingly low (21). Within the cerebellum, IL-33 expressing
cells are scattered through the granular, and white matter layers
with no expression detected in the molecular layer (Figure 1E).
Co-localization of IL-33 with various CNS resident cells has
been reported across brain regions (Table 1). Within the CC,
IL-33 is predominantly expressed by astrocytes (not all though)
in murine tissues using GFAP (Figure 2A) or S-100 antibodies
(27). High level of co-expression with Oligo2+ oligodendrocytes
is also shown within this region (21), which is enhanced by
Poly-IC treatment after gliotoxic injury and therefore promotes
oligodendrocyte progenitor cell (OPC) maturation and myelin
production (27). Whether IL-33 is expressed by microglia and
neuron cells is less clear and remains controversial (Table 1).
IL-33 colocalisation with Iba-1+ microglia and neuronal somas
(NeuN+) (Figure 2A) in CC region is evident however at
much lower levels. In the hippocampus, the low level of IL-
33 expression appears to co-localize with GFAP+ astrocytes
predominantly within the stratum oriens and stratum radiatum
layers of the CA1, CA2, and CA3 region as well as molecular
layer of the dentate gyrus (DG; Figure 2B). Consistent with
previous findings (21), low level neuronal expression of IL-33 is
observed in the granular layer (Figure 2B) within the DG, while
low number of IL-33-expressing microglia was also observed in
the polymorph layer of the DG (Figure 2B) (21).
The spinal cord is made up of bundles of nerve fibers and
forms an important part of the CNS. Currently it is not clear
whether IL-33/ST2 exhibit different roles in the spinal cord
compared to brain. Data of IL-33 expression in the spinal cord
has been primarily documented in animal studies (Figure 2C)
(16, 29, 30, 34). In contrast to its abundant expression in the white
matter region in brain (12), IL-33 immune reactivity is prominent
in spinal cord gray matter and significantly lower in the white
matter (29). This suggests potentially different functions of IL-
33 in brain and spinal cord. Similar to findings in the brain,
IL-33 is shown to be expressed by oligodendrocytes (34) and
astrocytes (29, 30) (Figure 2C). In a recent study, Vainchtein
et al. identified astrocytes as the primary source of local IL-
33 in both brain and spinal cord using two IL-33 reporter
mouse models (16). Further evidence also suggests that IL-
33 is expressed by a limited number of NeuN+ neurons and
Iba1+ microglia cells (Figure 2C), similar to its expression in
brain.
ST2 Expression
Extracellular IL-33 exerts its effect through binding to its
receptor which consists of a heterodimer between ST2 and
IL-1RAcP (4). Although the expression pattern and cellular
distribution of ST2 in CNS remains understudied and somewhat
disputed, there has been some exciting progress in recent
years identifying IL-33 target cells. This has provided new
insights into the functional mechanisms of the signaling pathway
in CNS.
Expression of ST2 in the brain appears to mirror IL-33
expression in regard to distribution pattern. This includes regions
such as the olfactory bulb, hippocampus, and hippocampal
fringe; anterior commissure; CC as well as a number of
other regions throughout the cortex, in particular within the
somatosensory regions (S1FL/HL; Figure 3A). ST2 expression
within the cerebellum is distinct with low levels in the granular
and white matter layer, and likely on Purkinje cells (personal
observation), a class of GABAergic neurons located in the
cerebellum and cerebellar nuclei which play a fundamental
role in controlling motor movement. Whether IL-33/ST2 in
cerebellum region relates to motor movement activities is not
clear. In contrast to the low level of IL-33 expression observed
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FIGURE 1 | Expression of IL-33 in several brain regions. Brains from C57BL/6 mice were sectioned coronally and immunohistochemically stained for the expression
of IL-33 (red/brown) and counterstained with haematoxylin. (A–C) IL-33 is predominantly expressed in several white matter rich regions including (A) anterior forceps
of corpus collosum (fmi); (B) anterior commissure (aco) and (C) the hippocampal fringe (ﬁ) and stria terminalus (st). (D) Within the cortex, IL-33 is expressed at low
levels in the somatosensory (S1) and motor cortex regions (M1/M2). (E) In the cerebellum, IL-33 is expressed through the granular, and white matter regions with
minimal expression within the molecular layer. Arrowheads indicate IL-33+ cells. CPu, striatum; Cg, cingulate cortex. Scale bars represent 100µm.
in the hippocampus (Figure 2B), ST2 is highly expressed
throughout all regions which include CA1-CA3 and DG
(Figure 3B).
Different CNS cells have been proposed as IL-33 target
cells (Table 2). St2 mRNA was initially identified in cultured
murine astrocytes and microglia (14). However only microglia,
not astrocytes, neurons or any other CNS cells, flow-sorted
from thalamus region tissues are confirmed to express St2 (16).
Extensive staining in naïve mouse brain tissue demonstrates
that within the CC region, ST2 is surprisingly expressed
by some astrocytes, with lower expression level observed in
neuron cell bodies and microglia (Figure 4A). Prominent but
not complete neuronal co-localization is also seen in the
cortex (Figure 4B), indicating the presence of ST2 on other
CNS cell types such as GFAP+ astrocytes (Figure 4B). The
expression of ST2 on astrocytes close to the endothelial layer
of the cortex is interesting, as these cells could be involved in
the astrocytic interactions with endothelial cells and pericytes
making up the blood brain barrier (BBB) (38). IL-33 may interact
with the BBB via these ST2+ astrocytes as reported in an
experimental cerebral malaria (ECM) model (39). Furthermore,
ST2 expression in various brain regions changes under different
conditions, e.g., the level is upregulated in the lesion of ischemic
brain (28).
The expression of ST2 in the spinal cord was confirmed
years ago (29) however it is yet to be agreed which CNS
cell population is the target for IL-33. Findings from several
groups have indicated that neurons (29, 33, 35), astrocytes
(33, 35) and oligodendrocytes (35, 37) can all express ST2
in the spinal cord as also shown in Figure 4C. Neuronal
expression of ST2 within the gray matter is particularly evident
(Figure 4C) and its staining pattern is consistent with the
morphology of neurons, which was confirmed by dual staining
with NeuN antibody. Less is known about ST2 expression by
spinal cord microglia cells (33, 35). Immunohistochemical
staining of naïve mouse tissue confirms the expression of
ST2 in some astrocytes and microglia (Figure 4C), albeit
at far lower levels. In the inflammatory spinal cord of
experimental autoimmune encephalomyelitis (EAE) mice,
mRNA of St2 is shown to be increased (29) and the upregulation
is predominantly in the lesion area in the white matter
(29, 37).
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TABLE 1 | Expression of IL-33 in central nervous system cells.
CNS Tissue Neuron (NeuN Ab
or stated)
Astrocyte (GFAP Ab
or stated)
Microglia (Iba-1 Ab
or stated)
Oligodendrocytes
(Olig 2 Ab or stated)
References
Mouse mixed glia culture: Il33 mRNA ND
√
ND NT (14)
Mouse mixed glial culture NT
√
NT NT (24)
Mouse mixed glial culture NT
√
NT
√
(17)
Mouse mixed glial culture NT
√
NT
√
(25)
Mouse P9 brain ND in most MAP-2+
cells
√
NT
√
(17)
Rat brain
√ √
ND NT (26)
Rat brain NT
√√
(S-100) Infrequent (CD68)
√
(27)
MS patient brain NT
√
NT NT (19)
Healthy and MS brain
√
(SMI-31)
√ √ √
(CA-II) (13)
Mouse brain ND (MAP-2 and DCX)
√
ND
√
(25)
Mouse brain
√
(ventral dentate
gyrus)
√
(S-100β) ND
√
(21)
Mouse brain ND
√
ND
√
(CC-1, not NG2) (28)
Mouse brain NT
√
NT NT (18)
Mouse thalamus and spinal cord NT
√
(ALDH1L1) NT
√
(CC-1) (16)
Mouse spinal cord
√ √
NT NT (29)
Mouse spinal dorsal horn ND
√
ND (CD11b) NT (30)
Mouse spinal cord ND
√
ND NT (31)
Mouse spinal cord
√ √
ND (CD11b) NT (32)
Mouse spinal cord ND
√
ND (CD11b) NT (33)
Mouse spinal cord Minimal to none
√
(ALDH1L1) Minimal to none
√
(Olig2+CC-1) (12)
Mouse spinal cord
√ √ √ √
(34)
Rat spinal cord
√ √
ND (OX-42)
√
(35)
Expression of Il33 mRNA was performed using PCR while protein expression was studied using immunohistochemical staining and other methods.
√
, positive expression of IL-33; ND,
not detectable; NT in gray square, not tested. Ab, antibody; MS, multiple sclerosis.
Implications of IL-33 and ST2 Expression in
CNS
Thus, the current research evidence illustrates a complex
pattern of IL-33 and ST2 expression in CNS tissue and cells.
The variation of the expression levels in different regions of
the CNS may indicate that the IL-33/ST2 signaling pathway
has specific roles in different regions. For example, CC
region is the largest commissure in the brain connecting
both hemispheres homologous regions and providing
interhemispheric communication (40). It is also involved
in a number of CNS inflammatory diseases including MS (41, 42)
and cerebral malaria (25). High levels of both IL-33 and ST2
positive cells in the CCmay imply a role of the signaling pathway
in these diseases. While it is surprising that IL-33 expression in
hippocampus is low, high levels of ST2 expression in the region
may indicate an important hippocampal response to IL-33
released from nearby tissues following injury/inflammation.
Numerous studies have substantiated that astrocytes
and oligodendrocytes are the predominant source of IL-33
production, while its expression on neurons and microglia
(Table 1) is less consistent and requires further investigation.
Once produced, IL-33 acts through binding to ST2 receptor
expressed by various cell populations including microglia,
oligodendrocytes, astrocytes and neurons. The variation
and disagreement about IL-33+ and ST2+ cells in CNS
tissues between reports (Tables 1, 2) may be explained by the
heterogeneity of each type of CNS cell. For example astrocytes
differ in morphology, receptor expression, and function across
different CNS regions, this has been reported in both mice
and human (43–45). Furthermore, without doubt, the dynamic
neurological and immunological changes within the tissue under
various physiopathological conditions also contribute to the
complex heterogeneity of CNS resident cells. This inevitably
influences the expression of IL-33 and ST2 on these cells. IL-33
expression is increased in the CNS of MS patients (13) but the
level is decreased in AD (46). ST2 expression is significantly
increased in the spinal cord lesions composed of infiltrating
immune cells in EAE mice (37), and in microglia which are
essential in mitigating the severity of ischemic lesions in mice
(28). Gadani et al. even discovered a flip of the expression
levels of St2 gene between CD11b+ microglia and CD11b−
astrocyte cell populations before and after injury (12). It is also
important to note the different methods used to determine the
molecule expression in tissues, e.g., Il-33 reporter mice (16, 25)
or immunohistochemical staining. Although there is variation
in the quality of the IL-33 and ST2 antibodies used in different
experiments, IL-33−/− mice (21) or specific blocking peptides
(36) are used in some but not all studies to verify the specificity
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FIGURE 2 | IL-33 expression by CNS resident cells in mouse brain and spinal cord. Tissues from C57BL/6 mice were sectioned and immunohistochemically stained
for the expression of IL-33 (brown), and astrocytes (GFAP), neurons (NeuN) and microglia (Iba-1) (all blue) within the (A) corpus callosum and (B) hippocampus and
IL-33 co-localization assessed. RSG, retrosplenial granular cortex; CC, corpus callosum; DG, dentate gyrus; CA1-3, hippocampus. (C) In spinal cord, the majority of
IL-33 expressing cells are localized to the GM, with lower levels present in the WM. IL-33 is expressed by GFAP+ astrocytes in both GM and WM regions with lower
level co-localization with neurons and microglia in the GM and, GM/WM, respectively. Arrowheads indicate IL-33+ cells, arrows indicate NeuN, GFAP or Iba-1+ cells
and asterisks indicate double positive cells. GM, gray matter; WM, white matter. Scale bars represent 100µm.
of the antibodies. Improvement in the standards for antibody
validation is therefore essential in the future.
Taken together, the dynamic expression of IL-33 and its
receptor ST2 within the CNS regions and cells indicates a
complex network of communication between the immune and
CNS resident cells. This underscores the fundamental role
endogenous IL-33/ST2 signaling pathway plays in the CNS under
physiological and pathological conditions.
ROLE OF IL-33/ST2 AXIS IN CNS
DEVELOPMENT AND FUNCTION
Despite recent effort, whether IL-33 has detrimental or
beneficial effects on the growth and function of neurons is
still undetermined. 10 ng/ml of recombinant IL-33 (rIL-33)
in a mouse mixed glia cell culture or pure neuronal culture
decreases neuronal number together with the loss of neuritis-
like appearance when compared with untreated control neurons
(47). However 25 or 100 ng/ml of rIL-33 has no significant
impact on the growth or viability of neurons and axonal
densities in a rat myelinating culture system (13). Similarly,
there is contradictory evidence regarding the role of IL-33/ST2
axis in CNS myelination. Treatment with rIL-33 promotes
the differentiation and maturation of rat OPCs cultured in
vitro (27), but fails to improve axonal myelination in a rat
myelinating culture as the treatment significantly reduces the
proportion of myelinated axons (13). It is worth noting that
this inhibitory effect on myelination is not observed in a mouse
myelinating culture system (13). This may indicate an important
species-specific difference or indeed culture condition difference
resulting in the discrepancy reported by different research
groups. Nevertheless, the above findings, together with the recent
identification of ST2 expression by oligodendrocytes (Table 2)
indicate an important role for IL-33/ST2 signaling pathway in
the myelination process during the CNS development, and also
likely the repair phase in demyelinating diseases such as MS.
Additionally, ST2 is shown to be expressed in small to medium-
sized dorsal root ganglion (DRG) neurons and IL-33 induces
Ca2+ influx into a subsets of neurons dissociated from the
cervical DRG, suggesting IL-33/ST2 signaling excites sensory
neurons (36).
The unique role of IL-33 in CNS physiological function in
vivo has been reported using Il33 gene knockout mice (21).
Deficiency of Il33 alters the expression of c-Fos proteins, an
indicator of neuronal activities, in brain regions implicated in
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FIGURE 3 | Expression of ST2 in mouse brain regions. Brains from C57BL/6 mice were sectioned coronally and stained for the expression of ST2 (red/brown) and
counterstained with haematoxylin. (A) Within the cortex, ST2 was expressed at high levels in the somatosensory (S1) and motor cortex regions (M1/M2). (B) ST2 was
also highly expressed throughout the hippocampus (CA1–CA3) including the dentate gyrus (DG). Arrowheads indicate ST2+ cells. CPu, striatum; Cg, cingulate
cortex. Scale bars represent 100µm.
anxiety-related behaviors. These IL-33 deficient mice exhibit
reduced anxiety-like behaviors, as well as deficits in social novelty
recognition, despite intact sociability (21). The authors suggest
that IL-33 may regulate the development and/or maturation
of neuronal circuits, rather than control neuronal activities in
adult mice. Indeed IL-33 mediated signaling is required in
brain development (16). IL-33 deficient mice contain an excess
number of excitatory synapse and show deficits in acoustic startle
response, a sensorimotor reflex mediated by motor neurons in
the brain stem and spinal cord. Furthermore, IL-33 produced by
synapse-associated astrocytes is required for the development of
normal synapse numbers and circuit function in the thalamus
and spinal cord, signaling primarily through microglia cells
under physiologic conditions to promote increased synaptic
engulfment (16).
While the above findings reveal a key role for IL-33 during
CNS development and activities in some brain regions, it is
important to remember that the mechanisms of action of the IL-
33/ST2 axis in the CNS are likely to be complicated and engage
the multi-cell network consisting of neurons, oligodendrocytes,
astrocytes, and microglia cells. The findings of IL-33 involvement
in exciting sensory neurons, axonal myelination and synapse
homeostasis also imply that dysregulated IL-33/ST2 signaling
may lead to CNS neurological and behavioral disorders.
ROLE OF IL-33/ST2 AXIS IN CNS DISEASE
Alzheimer’s Disease
AD is the most common form of dementia and its pathology
can be characterized by extracellular amyloid deposits- made of
Aβ peptides- and intracellular tau-based neurofibrillary tangles
(NFTs) (48). Genetic studies have identified single nucleotide
polymorphisms (SNPs) within Il-33 to be associated with a
decreased risk of developing AD in Caucasian (46) and Han
Chinese populations (49, 50). It is not yet clear how the
expression levels of IL-33 and ST2 in tissues correlate with AD.
Chapuis observed a reduced level of IL-33 expression in the
brains of AD patients (46). However, increased IL-33 and ST2
levels are found in proximity to amyloid plaques and NFTs in
AD patients in comparison to healthy controls (51). Patients with
mild cognitive impairment, who have an increased risk of AD
development, also exhibit a significantly higher serum level of
sST2 (52).
It remains debatable whether and how IL-33 affects AD. The
induction of IL-33 production by β-amyloid peptide in astrocytes
at the vicinity of plaques indicates IL-33 may contribute to AD
pathogenesis as one of the inflammatory molecules (51). Indeed
an effective treatment with a nanomaterial inAPP/PS1 transgenic
mice, a transgenic animal model of amyloid deposition, shows
improved learning and memory capability associated with
decreased levels of several pro-inflammatory cytokines including
IL-33 (53). Other investigators disagree and have presented
research evidence to substantiate a potentially therapeutic role for
IL-33 in AD (18, 46, 52). Systemic injection of rIL-33 in APP/PS1
mice reverses synaptic plasticity impairment andmemory deficits
with reduced soluble Aβ levels and amyloid plaque deposition
(52). This is likely mediated by promoting the recruitment of
microglia and enhancing their Aβ phagocytic activity. Their
subsequent experiments revealed that IL-33 polarizes microglia
and macrophages toward an anti-inflammatory M2 phenotype, a
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TABLE 2 | Expression of IL-33 receptor ST2 in central nervous system cells.
Tissue or cells Neuron (NeuN Ab
or stated)
Astrocyte (GFAP Ab
or stated)
Microglia
(Ab tested)
Oligodendrocytes
(Olig 2 Ab or stated)
References
Mouse mixed glia culture: St2 and IL-1RAcP mRNA
√
(IL-1RAcP only)
√ √
NT (14)
Mouse mixed glia culture: St2 mRNA NT
√ √
NT (12)
Rat myelinating co-culture
√
ND NT
√
(O4) (13)
MS patient brain
√
(SMI-31) NT NT
√
(CA-II) (13)
Mouse brain ND (by FC)
√
(GLAST) (by FC)
√
(Iba-1) ND (by FC) (28)
Mouse thalamus and spinal cord ﬂow sorted cells (St2 mRNA) ND ND
√
NT (16)
Mouse spinal cord
√
ND NT NT (29)
Mouse spinal cord
√ √
ND (CD11b) NT (36)
Mouse dorsal root ganglia
√
(Nissi) NT NT NT (36)
Human DRG: St2 and IL-1RAcP mRNA
√
NT NT NT (36)
Mouse spinal cord (EAE) NT
√
NT
√
(O1) (37)
Rat spinal cord
√ √
ND (OX-42)
√
(35)
Expression of St2 mRNA was performed using PCR while protein expression was studied using immunohistochemical staining or other methods.
√
, positive expression of ST2; ND,
not detectable; NT in gray square, not tested. Ab, antibody; EAE, experimental autoimmune encephalomyelitis; FC, flow cytometry; MS, multiple sclerosis; DRG, dorsal root ganglia.
FIGURE 4 | ST2 expression by CNS resident cells in mouse brain and spinal cord. Tissues from C57BL/6 mice were sectioned and stained for the expression of ST2
(brown) and astrocytes (GFAP), neurons (NeuN) and microglia (Iba-1) (all blue) within the (A) corpus callosum and (B) hippocampus and ST2 co-localization assessed.
The majority of ST2 expressing cells co-localized with GFAP+ astrocytes while low level co-localization with neurons and microglia was observed in both regions. (C)
In spinal cord, the majority of ST2 expressing cells were localized to the GM, with lower levels present in the WM. ST2 was expressed by NeuN+ neurons in both GM
and WM regions with lower level co-localization with astroyctes and microglia. Arrowheads indicate ST2+ cells, arrows indicate NeuN, GFAP or Iba-1+ cells and
asterisks indicate double positive cells. cc, corpus callosum; GM, gray matter; WM, white matter. Scale bars represent 100µm.
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well-recognized mechanism of IL-33 action in several immune-
mediated diseases including spinal cord injury (12), asthma
(54), and EAE (29). Such a beneficial role of IL-33 in AD is
further supported in a study using aging mice. IL-33 expression
in astrocytes is dramatically increased by up to 74% in aged
mice, which appears to be critical for the repair of aged neurons
(18). Conversely IL-33 deficient mice have an uncontrolled
surge of neuronal aging due to failed repair at middle age and
ultimately develop neurodegeneration and late-onset AD-like
symptoms in old age (18). This is characterized by Tau deposition
and heavy neuronal loss in both the cerebral cortex and the
hippocampus and accompanied with cognition and memory
impairment. These findings indicate a critical role for IL-33 in
the maintenance and repair of aging and stressed neurons.
In summary, further investigation is required to determine
whether and how the changed levels of IL-33, ST2 and/or
sST2 in CNS tissues imply a specific role of IL-33/ST2
signaling pathway in AD. Evidences from in vivo research using
animal models support a neuroprotective role by modulating
neuroinflammation and promoting neuronal repair process,
indicating a potential IL-33 based novel therapeutic strategy for
AD patients.
Multiple Sclerosis
The involvement of IL-33 in the development of MS, a CNS
inflammatory demyelinating autoimmune disease, has been
supported by the increased expression of IL-33 and/or ST2 in
the CNS lesions of MS patients (13, 19) and EAE mice (29,
55). In addition, effective treatment in EAE rats downregulates
IL-33/ST2 expression (55). However, its precise function in
disease development remains controversial (29, 32, 56). While
Li et al. reported a detrimental effect of IL-33 treatment
on EAE severity (56), others argue a protective role for the
cytokine in attenuating EAE. The studies suggest IL-33 inhibits
EAE development through mechanisms such as promoting
type 2 T cell- and macrophage-mediated immune responses and
inhibiting production of IL-17 and IFN-γ (11, 29). A more recent
investigation suggests that a dramatic decrease of intracellular
IL-33 is accompanied by increased extracellular IL-33 in the
spinal cord of EAE mice (32). This subsequently promotes
the expansion and function of ST2+ Treg cells in inhibiting
CNS inflammation. Interestingly, IL-33 has been reported to
regulate sex-dimorphic susceptibility of MS (57). Male-specific
expression of IL-33 by mast cells expands ST2 positive (58)
type 2 innate lymphoid cells (ILC2s) and drives a Th2 immune
response in attenuating EAE clinical symptoms in mice. To
date no data are available indicating a gender-based differential
expression/production of IL-33 and/or ST2 in tissues of other
sex-biased diseases. The involvement of mast cells and ILC2s as
the mediating cells in the above study indicates that this special
function of IL-33 is unlikely to be limited to CNS diseases. Thus,
future studies in immune disorders with pronounced gender
differences such as systemic lupus erythematosus and ankylosing
spondylitis may provide improved knowledge of the molecular
basis of sex-dimorphic disease.
Another emerging issue of recent debate is whether IL-33/ST2
plays an important role in remyelination, an essential CNS repair
process in MS. This is of particular interest after the confirmation
of ST2 expression on oligodendrocytes (12, 13). Despite the
findings that rIL-33 reduces the proportion of myelinated axons
in a rat myelinating culture (13), higher levels of IL-33 expression
are observed in tissues with higher myelin content in vivo
(12). rIL-33 also promotes the differentiation and maturation
of rat oligodentrocytes in culture as shown with increased
transcription of myelin genes and phosphorylation of p38MAPK,
a signaling molecule involved in myelination (27). Furthermore,
in vivo subcutaneous administration of Poly-IC results in greater
recruitment of OPCs and enhances remyelination following
gliotoxic injury with lysolecithin to the brain CC region (27). This
is associated with increased expression of IL-33 in astrocytes and
an upregulation of Arg and CD206 in macrophages (indicating
they are type 2 like macrophages) in the local region.
Therefore, it is clear that current research findings support
the involvement of IL-33/ST2 axis in MS development through
modulating both the immune response and the CNS repair
process. However, its precise function remains to be determined
before any potential strategies of therapies can be developed for
patients.
Schizophrenia
Schizophrenia is a complex neuropsychiatric disorder which
is characterized by a heterogeneous combination of symptoms
such as hallucinations and delusions, social withdrawal as well
as cognitive impairment. It affects approximately 1% of the
worldwide population, with its pathogenesis yet to be fully
characterized. Recent studies have shown that specific cytokines
might be the neurobiological mediators underlying the pathology
of the disease (59). Elevated levels of inflammatory cytokines such
as IL-1β, IL-12, IFN-γ, and TNF-α are detected both in the brain
and blood of schizophrenia patients (60). Furthermore, increased
levels of serum IL-18 is positively associated with cognitive
deficits in schizophrenia patients (61). To date very little is known
about IL-33 in schizophrenia. However, the expression of IL-
33 and ST2 in schizophrenia associated brain regions such as
prefrontal cortex, basal ganglia, hippocampus, and amygdala
(62–65) may suggest its involvement in disease development.
Indeed polymorphism of IL-33 is associated with decreased
susceptibility to schizophrenia within an Iranian population (66).
Additionally, increased levels of serum IL-33 and sST2 correlate
with improved cognitive performance in schizophrenia patients,
although no difference of either molecules is observed between
patients with schizophrenia and healthy controls (67).
Schizophrenia patients frequently exhibit behavioral
abnormalities such as enhanced persistence of resting and
active periods of locomotor activities (68). IL-33 deficient mice
display multiple behavioral deficits such as reduced anxiety and
impaired social recognition (21). However, these mice show
no obvious changes in locomotor activities, with the exception
of older mice (60 weeks old) at which point the activities are
increased (18). Naïve adult age (8–10 weeks) mice receiving
intraperitoneal injection of rIL-33 do not show any change in
locomotor activity when analyzing parameters such as distance
moved, velocity, rotations and meander in an open-field test
(personal observation). Interestingly in a mouse model of
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schizophrenia induced by phencyclidine (PCP) (69–71), a non-
competitive antagonist of the N-methyl-D-aspartate (NMDA)
receptor (72, 73), rIL-33 dramatically increases the PCP-induced
locomotor activity. This is characterized by increased animal
moving distance and velocity in open-field tests relative to PCP
mice (Figures 5A–C; P < 0.0001).
The effect of IL-33/ST2 signaling pathway on locomotor
activity in both aging (18) and PCP treated mice, but not normal
age naïve mice, is very interesting and important. Future studies
should reveal whether the IL-33/ST2 signaling pathway only
influences locomotor activity in individuals with specific CNS
conditions. The underlying mechanism of altered locomotor
activities by IL-33 remains unclear, however as an antagonist
of NMDA receptors, IL-33 may act on glutamate synapses in a
synergistic fashion similarly to IL-1β (74) and TNF-α (75). It is
also possible that IL-33 may influence the secretion of glutamine
synthetase by astrocytes. This would potentially have an impact
on the ability of astrocytes to protect neurons from excitotoxicity
which has been shown before with IL-1β and TNF-α (76).
CNS Injury
CNS traumatic or ischemic injury is one of the leading causes of
death and permanent disability worldwide. Neuroinflammation,
often characterized by type 1 or type 2 immune responses
(although an oversimplified description, but helpful in our
understanding of the immune responses in diseases), is a
prominent feature of CNS injury and highly influences CNS
repair and thus the injury recovery process (77–80). As a nuclear
alarmin molecule released by damaged dying cells (6) and
as an important immunomodulatory cytokine, IL-33 plays an
important role in the pathophysiology of CNS injury.
An association between IL-33/ST2 signaling pathway andCNS
ischaemic injury has been highlighted by the findings of elevated
level of sST2 in the plasma of stroke patients and its correlation
with a worsened clinical outcome (81). Significantly increased
level of serum IL-33 is also detected in patients with acute
ischemic stroke (AIS) compared with healthy controls (82), and
is shown to be a novel diagnostic and prognostic biomarker for
AIS. Patients with higher IL-33 demonstrate a favorable outcome
3 months after the stroke. In a mouse model of stroke, the
expression of IL-33 by oligodendrocytes and astrocytes is rapidly
increased together with an upregulation of ST2 on microglia
after inducing ischemic brain injury (28). Increased ischemic
lesion size and long term behavioral deficits are observed in
ST2 deficient mice in comparison to the wild type controls
indicating a possible protective role of IL-33 in stroke (28).
Indeed administration of rIL-33 locally (28, 83) or peripherally
(81) reduces stroke-induced CNS damage and ameliorates
neurological deficits via inducing anti-inflammatory responses
systemically andM2 typemacrophages andmicroglia in the CNS.
This occurs at least partially in an IL-4-dependent manner (81).
Meanwhile infusion of rIL-33 intracerebroventricularly protects
mice from ischemic injury by inducing a switch from Th1 to
Th2 and suppressing Th17 responses (83), or by potentiating
the expression of IL-10 and other M2 genes in microglia (28).
Indeed mice deficient in ST2 gene have impaired expression of
M2 polarizing markers (28).
The IL-33/ST2 signaling pathway is also closely involved
in the neuroinflammatory response following CNS traumatic
injury. Significantly increased levels of IL-33, likely released
by oligodendrocytes (12) and astrocytes (31), are detected in
injured spinal cord segments (12, 31) and in the cerebrospinal
fluid (CSF) (12). Gadani et al. further discovered that the
baseline expression level of St2 transcript by astrocytes is
low but significantly elevated after injury. At the same time
its expression level on microglia is shifted from high at
baseline to low after injury. From these data the authors
concluded that astrocytes but not microglia are likely to be the
primary target cells of IL-33 mediating the neuroinflammation
after injury. It also confirms the dynamic change of IL-33
expression in CNS tissues under diseased conditions (12).
Mice with spinal cord injury exhibit significantly reduced
tissue damage, demyelination and astrogliosis after treatment
with rIL-33 (31). This is associated with suppressed pro-
inflammatory immune responses and biased anti-inflammatory
M2 microglia/macrophages and Treg cells both locally in the
spinal cord and systemically (31). On the contrary, mice
deficient of IL-33 gene develop increased lesion size together
with significantly decreased number of M2 microglia and
macrophages (12). The investigators further demonstrated that
IL-33 released from damaged oligodendrocytes upon injury
orchestrates the production of various chemokines such as
CCL2 and CXCL2 by astrocytes, resulting in the recruitment of
monocytes into the CNS. As a potent activator of ST2 expressing
ILC2s (39, 58, 84), IL-33 released into the CSF immediately
after injury also mediates CNS inflammation through the newly
discovered meningeal ILC2s (85). IL-33 therefore is released as
an alarmin after injury to orchestrate the activations of both CNS
cells and immune cells with the aim to promote recovery (12).
Taken together, in both ischemic and traumatic CNS injury,
IL-33 signaling appears to be beneficial. IL-33 released by
damaged oligodendrocytes, astrocytes and possibly other cells
at the injury site coordinates the immune responses mediated
by CNS resident cells, meningeal ILC2s and infiltrating immune
cells. This ultimately promotes a type 2-like neuroinflammation
and confers protection from tissue damage and neurological
deficit.
Pain
Given the prevalence of chronic pain and the fact that current
treatment only provides moderate degrees of relief, it is
both challenging and important to understand the molecular
mechanisms of pain. Over the years astrocytes and microglia
cells have emerged as key contributors to the pathological
development of pain (86) through releasing a number of
important molecules such as IL-33.
IL-33 was first identified as a key mediator of inflammatory
hypernociception in an animal model of arthritis (87), and
in carrageenan-induced inflammatory pain likely through
triggering the production of inflammatory mediators such
as TNF-α (88). In a more recent study, Zarpelon et al.
show that intrathecal injection of IL-33 induces hyperalgesia
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FIGURE 5 | IL-33 enhances PCP-induced changes in locomotor activity. (A) C57BL/6 mice were ﬁrst habituated inside a 40 × 40cm open ﬁeld maze for 1 h before
being taken out of the maze and injected intraperitoneally with vehicle control (PBS) or 200 ng IL-33. After 15min mice received an i.p. injection of either PBS or PCP
(5 mg/kg), and were then placed back into the same open ﬁeld maze for 1 h. Their (B) distance moved and (C) velocity were tracked via overhead cameras and
analyzed. Signiﬁcant (p < 0.05) pairwise differences according to Tukey’s post hoc test show PCP_IL-33 > PCP > naïve and IL-33 for both distance moved and
velocity. LMA: locomotor activity.
in naïve mice and enhances hyperalgesia caused by chronic
constriction injury (CCI) (34). Furthermore, hyperalgesia is
reduced in mice deficient of St2 gene or treated with IL-
33 decoy receptor sST2 suggesting IL-33 has an important
role in neuropathic pain. The group further demonstrated IL-
33 is mainly produced by spinal cord oligodendrocytes after
CCI which subsequently acts on astrocytes and microglia.
Furthermore, IL-33-mediated hyperalgesia is dependent on a
reciprocal relationship with TNF-α and IL-1β. This mechanism
of action of IL-33 is supported by findings from a rat
model of radicular pain (35). Non-compressive lumbar disc
herniation induces expression of IL-33 and ST2 in the
spinal cord which subsequently mediates the development and
progression of radicular pain through modulating TNF-α, IL-
1β, and COX-2. The pathogenic contribution of IL-33 toward
pain is further confirmed in a spared nerve injury induced
neuropathic pain model (33). Blocking of IL-33/ST2 signaling
with ST2 neutralizing antibody or St2 gene depletion significantly
attenuates mechanical and cold allodynia. Liu et al. reported
that IL-33 induced nociceptive behavior involves the spinal
NMDAR and is mediated through activation of the astroglial
JAK2–STAT3 cascade and the neuronal CaMKII–CREB cascade
(33).
Confirming the pathological contribution of IL-33/ST2
signaling pathway in pain development, effective reduction
of CCI induced pain by different analgesics is shown to
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TABLE 3 | Role of IL-33/ST2 axis in neurological disease.
Disease Role of IL-33 References
Alzheimer disease (AD) • Reduced IL-33 expression in AD brain; Il33 genetic variants associate with a decrease risk in AD (46)
• Increased IL-33 and ST2 in AD brains, Aβ induces IL-33 production by astrocytes to mediate AD pathogenesis (51)
• Increased sST2 in serum of AD patients; IL-33 reduces Aβ levels and amyloid plagues and reverses synaptic
plasticity impairment and memory deﬁcit in a mouse model
(52)
• Effective treatment of APP/PS1 mice with improved learning and memory capability is associated with reduced
level of IL-33
(53)
• IL-33 expression in astrocytes increases with age and IL-33−/− aged mice display AD-like symptoms with tau
abnormality and neurodegeneration
(18)
Multiple sclerosis (MS) • Elevated IL-33 protein, mRNA levels in NAWM and plaque areas, and in plasma and PBMCs (19, 106)
• Enhanced expression of IL-33 and ST2 in MS CNS lesion (13)
• mRNA of IL-33 and ST2 increased in spinal cord of EAE rats (55)
• IL-33 blockade suppresses EAE development in mice (56)
• IL-33 attenuates EAE by inducing type 2 immune response (29)
• IL-33 released by astrocytes and neurons suppresses EAE (32)
• Male-speciﬁc IL-33 attenuates EAE through ILC2s and mast cells (57)
Pain • IL-33 is a key mediator of inﬂammatory hyper nociception (87)
• IL-33 mediates carrageenan-induced inﬂammatory pain via trigging TNF-α (88)
• IL-33 induces hyperalgesia in naïve mice and enhanced hyperalgesia in a mouse model of chronic constriction
injury via reciprocal relationship with TNF-α and IL-1β
(34)
• IL-33 inhibits electroacupuncture analgesia in formalin mice (92)
• Spinal IL-33 and ST2 contribute to bone cancer induced pain in mice (30)
• IL-33 contributes to neuropathic pain through activating astroglial and neuronal cascades, and up-regulate
NMDA
(33)
• IL-33 induced by non-compressive lumber disk herniation in rat mediates pain through TNF-α, IL-1β and COX-2 (35)
Psychiatric disorders • IL-33 polymorphism associates with decreased susceptibility to schizophrenia (66)
• Serum levels of IL-33 and sST2 positively correlate with cognitive performance in schizophrenia patients, but
with no difference between patients and controls
(67)
• IL-33−/− mice display multiple behavioral deﬁcits, e.g., reduced anxiety and impaired social recognition (21)
• IL-33−/− aged mice exhibit increased locomotor activities (18)
• IL-33, sST2 and IL-1β plasma levels are not changed in ASD patients (107)
• Reduced plasma IL-33 in ASD patients (108)
Stroke • sST2 is increased in plasma of stroke patients, IL-33 protects mice against stroke through IL-4 (81)
• IL-33 ameliorates brain injury in stroke model through promoting Th2 and suppressing Th17 responses (83)
• Increased serum IL-33 in acute ischemic stroke patients (82)
• IL-33/ST2 dependent microglial response limits acute ischemic brain injury (28)
Traumatic CNS injury • Oligodendrocyte-derived IL-33 induces M2 genes and aids the recovery of optic nerve injury in mice (12)
• IL-33 reduces secondary injury and improves recovery in a mouse contusion injury model through inducing Th2
and Treg responses
(31)
• IL-33 improves spinal cord injury via activating meningeal ILC2s to produce type 2 cytokines (85)
Cerebral malaria • IL-33 treatment reduces parasitaemia at early phase of infection through inducing type 2 immune responses (39)
• ST2 deﬁcient mice survived longer than WT after infection (97)
CNS encephalitis • Levels of IL-33 protein and mRNA increased in the serum and CSF of neuro-Behcet’s disease patients (109)
• IL-33 attenuates viral induced encephalitis by downregulating IFN-γ and NO production (110)
CNS Toxoplasmosis • ST2 Levels increased in brain of infected mice, ST2 deﬁcient mice had increased susceptibility, parasite burden
and encephalitis to cerebral infection
(95)
CNS hemorrhage • IL-33 encoding gene Dvs 27 is active after experimental subarachnoid hemorrhage (111)
• Il33 mRNA elevated in cerebral cortex in subarachnoid hemorrhage (26)
• IL-33 has neuroprotective effects in intracerebral hemorrhage in mouse (112)
be mediated through inhibition of the IL-33/ST2 signaling
pathway (89–91). This also agrees with a report by Han et
al. suggesting electro acupuncture analgesia alleviates formalin-
induced inflammatory pain in mice, at least partially, through
inhibition of spinal IL-33/ST2 signaling and the downstream
ERK and JNK pathways (92).
Based on the above findings, it is likely that IL-33/ST2
induces and/or augments pain in the nervous system through
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potentiating TNF-α and IL-1β mediated inflammation. Thus,
future therapeutic strategies for patients with pain may be
developed by targeting the IL-33/ST2 signaling pathway along
with current treatments.
CNS Parasitic Infection
IL-33 is important in limiting protozoan parasite infections
systemically (93, 94), with several studies particularly focused
on its role in neuropathology induced by parasite infections.
Toxoplasma gondii (T. gondii) is an obligate, intracellular
parasite which is able to persist, often asymptomatically, for a
lifetime within the CNS of immunocompetent hosts. St2 mRNA
is upregulated in the brain of mice infected with T. gondii
(95). ST2 deficient mice (T1/St2−/−) demonstrate an increased
susceptibility to cerebral infection with an increased parasite
burden and more severe encephalitis which is associated with
greater cerebral expression of iNOS, TNF-α and IFN-γ (95). This
indicates a possible protective role for IL-33/ST2 signaling in
T. gondii infection.
A specific role of IL-33 has been investigated in cerebral
malaria which is the most severe form of neurological
complications associated with Plasmodium falciparum infection.
It results in long term cognitive deficits, behavioral difficulties,
epilepsy, coma and, in many cases, death (96). Increased IL-
33 expression is shown in the brains of experimental cerebral
malaria (ECM) mice induced by murine Plasmodium berghei
ANKA (PbA) (25, 97), which is likely expressed by astrocytes
and oligodendrocytes (25). Meanwhile, ST2 deficient mice do
not exhibit ECM associated neurological signs or associated
cognitive deficits unlike their wild type counterparts despite
similar levels of parasitaemia and parasite load (25, 97). There
appears to be reduced neuroinflammation together with a
reduction in activated CD4+ and CD8+ T cells and pro-
inflammatory cytokines and chemokine levels within the brain
parenchyma of ST2 deficient mice. A potential feedback loop has
been further suggested between microglia and oligodendrocytes
in exacerbating neuroinflammation by the initial infection. IL-
33 stimulates IL-1β production by microglia, which in turn
induces IL-33 expression by oligodendrocytes (25). These results
suggest IL-33/ST2 signaling plays a role in promoting the
effector and cytotoxic T cell responses and enhancing the CNS
resident immune response, which combined contributes to the
neuropathology and cognitive deficits associated with ECM.
Paradoxically, administration of IL-33 in the early stages of ECM
improves animal survival time with reduced weight loss and
clinical score, but not from malaria-induced hyperparasitemia
and death compared to control mice (39). The study provided
further evidence of a protective immune response via IL-33-
induced ILC2s, M2 macrophages, and T regs. It is not known
what has caused the discrepancy between the above findings, the
data may highlight the difference between research approaches
using gene modified animals and exogenous administration of
reagents.
Thus, while the study by Jones et al. illustrates a protective
role for IL-33 in T. gondii infection (95), the precise
pathophysiological function of IL-33/ST2 in ECM remains to be
determined.
Glioma
The role of IL-33 in tumor progression has been illustrated
elsewhere, with overexpression of IL-33 identified as a diagnostic
and prognostic marker for several types of cancer (98–101).
Within the CNS, IL-33 is abundantly expressed by rat glioma
cells together with its receptor ST2 (102). In glioma patients,
increased expression of IL-33 (103, 104) and ST2 (104) is detected
in tumor tissues albeit heterogeneously, compared with normal
brain tissue (103). Zhang et al. also reported higher expression
of Il33 mRNA in glioma tissues than in normal brain tissue,
and that the level correlates with a shorter progression-free
survival and overall survival than those with low expression
(105). Furthermore, while there is no differential IL-33 protein
expression by tumor grade, elevated levels of IL-33 protein, and
mRNA are associated with inferior survival in patients with
recurrent glioblastomas. All of these data suggest a pivotal role
for IL-33 in the disease pathogenesis and as a potential biomarker
for prognosis of human gliomas.
It has become clear that the IL-33/ST2 signaling pathway
facilitates glioma cell proliferation and migration, as treatment of
the cells with IL-33 shRNA or ST2 shRNA reduces cell growth
and colony formation in culture and reduces tumor volume
in vivo (102). Further evidence indicates that the involvement
of IL-33 in glioma cell invasion and migration is through
upregulation of MMP2 and MMP9 via the ST2-NF-κB signaling
pathway (104).
Thus, IL-33 may become a useful biomarker in predicting
prognosis in glioma patients, and a novel therapeutic target for
glioma treatment.
Other CNS Diseases
Emerging evidence suggests that the role of IL-33 is not limited to
the diseases highlighted in this paper (Table 3) and is expanding
to other CNS diseases. Expression level of IL-33 is significantly
reduced while sST2 increased in the serum samples of amyotropic
lateral sclerosis patients (113). In a rat model of subarachnoid
hemorrhage (SAH), expression of IL-33 in the cerebral cortex
after injury is markedly elevated in the SAH together with IL-
1β and TNF-a (26). IL-33 signaling pathway is also shown to be
essential in attenuating viral-induced encephalitis development
by downregulating iNOS expression in the CNS (110). Although
it is not changed in autism spectrum disorder patients (107),
increased plasma level of IL-33 is also observed in bipolar
disorder patients (114). While it will take time to appreciate the
specific and important function of IL-33/ST2 in various CNS
disorders, future research progress will provide new knowledge
and lead to improved diagnosis and therapies for patients.
CONCLUSIONS
The broad expression of IL-33 and ST2 in different CNS regions
and cells, in addition to many well-documented immune cells,
suggests the involvement of IL-33/ST2 signaling pathway in
the complex network of multi-cell interaction between the
immune and nervous systems in CNS health and disease.
Scientific advancements during the last decade have provided
some initial insights into the diverse and pleiotropic role IL-33
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plays in certain aspects of CNS function and disease through
interactions between glia, neuron, and immune cells. However,
as the CNS is the most complex organ, and human disease
often displays multiple layers of pathophysiology, the challenge
now is to determine in more detail the intensive and dynamic
communications among the CNS resident and infiltrating cells.
This would enhance our understanding of the important roles
the IL-33/ST2 signaling pathway plays in CNS homoeostasis and
neurological disorders. These findings will advance our diagnosis
of CNS diseases, and develop novel effective therapeutics for
patients.
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